Writing in the latest issue of The Lancet, the doctors called for a study into reducing the number of inappropriate admissions.

BBC: Poor intensive care 'risking lives'

In 2011, the results of the AIM-HIGH study called into question the value of niacin in the treatment of cardiovascular disease in light of their inferiority to statins.

FORBES: Vioxx and Diclofenac: Why Are Two Heart Risky Pain Drugs Viewed Differently?

He oversaw a study called Enhance that turned into a disaster for the company.

FORBES: Key Vytorin Exec Has Left Merck

However, Merck previously ran another study with Vytorin called ENHANCE that calls into question the underlying perceived benefit of Vytorin.

FORBES: Cholesterol Drug Heart Study Continues, But Will Merck's Vytorin Really IMPROVE-IT?